Skip to main content
Clinical Trials/CTRI/2022/10/046910
CTRI/2022/10/046910
Not yet recruiting
未知

Comparison of the Fibroblast Growth Factor (FGF -23) and Beta 2 microglobulin (β2M) levels in patients of chronic kidney disease (CKD) undergoing Renal Replacement Therapy (Haemodialysis vs Hemodiafiltration)

DGAFMS0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
DGAFMS
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
DGAFMS

Eligibility Criteria

Inclusion Criteria

  • Eligible adults of CKD 5D aged at least 18 years of age who have been initiated on any one of the two modalities of dialysis
  • Individual should have functional AV fistula with blood flow more than 300 ml/min

Exclusion Criteria

  • Patients not having AV Fistula as vascular access in HDF and HD group
  • 2\. Patients not giving written informed consent will be excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials